Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Market Cap	$7.31B	P/E Ratio	N/A
52W High	$96.94	52W Low	$33.19
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-24.6%	52W Position	100.0%
Overall Score	53	Value Score	40
Quality Score	44	Technical Score	75

EPS Current Est	$-6.01	EPS Next Est	$-5.43
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MRUS	$96.93	+0.31%	708.55K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MRUS	$96.93	+0.3%	708.55K
3
4
5
6

MRUS

MRUS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Merus N.V. Data in Excel

Get Merus N.V. Data in Excel